N
Neurosterix
Developing allosteric modulator therapeutics for underserved neurological disorders,
About Neurosterix
Neurosterix is a biopharmaceutical company specializing in the development of allosteric modulators for the treatment of neurological disorders. These modulators are molecules that can increase or decrease the activity of target receptors by binding outside the traditional binding sites. This innovative approach aims to create drug candidates that offer improved efficacy, safety, and tolerability compared to existing treatments.
Read full description
The company primarily serves patient communities suffering from underserved neurological disorders, addressing a significant unmet medical need. Neurosterix operates in the biopharmaceutical market, focusing on drug discovery and development.
The business model revolves around leveraging its proprietary platform to identify and develop novel drug candidates. Revenue is generated through various channels, including partnerships with larger pharmaceutical companies, licensing agreements, and potentially through the commercialization of its own drug candidates.
At a glance
- Status
- Operational
- Founded
- 2024
- Headquarters
- Geneva, Switzerland
- Employees
- 30
- Open positions
- None listed
- Dealroom signal
- 90.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Biotech and Pharma, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Neurosterix.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Apr 2024 | $63M | $252M | Perceptive Advisors · Acorn Bioventures | ↗ |
Growth signals
Latest recorded traffic for Neurosterix is 1K monthly website visits, up 85.2% over the last three months. Neurosterix's team grew 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Perceptive Advisors
Acorn Bioventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neurosterix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neurosterix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.